As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out the advertisement of prescriptions for injectable weight-loss drugs without ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

It’s obvious these drugs are trimming waistlines across the nation; what may be less obvious is that they might also reshape ...

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several ...

The results suggest the potential of semaglutide – the main ingredient in Ozempic and Novo’s higher-dose weight-loss drug ...

Weight loss drugs like Ozempic and Wegovy dominated 2024. Securing insurance to cover the costs is a different challenge ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks ...

Eden is providing access to a new way for individuals to explore GLP-1 therapy: a compounded semaglutide gummy, available ...